Amir Mehrkar
A5032044970- COVID-19 Clinical Research Studies
- COVID-19 and healthcare impacts
- SARS-CoV-2 and COVID-19 Research
- Long-Term Effects of COVID-19
- Vaccine Coverage and Hesitancy
- COVID-19 and Mental Health
- Chronic Disease Management Strategies
- Healthcare cost, quality, practices
- COVID-19 epidemiological studies
- Antibiotic Use and Resistance
- Climate Change and Health Impacts
- Health disparities and outcomes
- Intensive Care Unit Cognitive Disorders
- Global Health Care Issues
- Venous Thromboembolism Diagnosis and Management
- Patient Satisfaction in Healthcare
- Frailty in Older Adults
- Influenza Virus Research Studies
- Atrial Fibrillation Management and Outcomes
- Emergency and Acute Care Studies
- Telemedicine and Telehealth Implementation
- Healthcare Systems and Technology
- Healthcare Systems and Challenges
- Pneumonia and Respiratory Infections
- Respiratory Support and Mechanisms
University of Oxford
2020-2024
National Health Service
2024
Nuffield Health
2021-2024
Science Oxford
2024
Bennett University
2023
Wellcome Trust
2023
Medical Research Council
2023
UK Research and Innovation
2023
London School of Hygiene & Tropical Medicine
2023
Health Data Research UK
2023
Abstract Background Establishing who is at risk from a novel rapidly arising cause of death, and why, requires new approach to epidemiological research with very large datasets timely data. Working on behalf NHS England we therefore set out deliver secure pseudonymised analytics platform inside the data centre major primary care electronic health records vendor establishing coverage across detailed for substantial proportion all patients in England. The following results are preliminary....
SummaryBackgroundWhether HIV infection is associated with risk of death due to COVID-19 unclear. We aimed investigate this association in a large-scale population-based study England.MethodsWe did retrospective cohort study. Working on behalf NHS England, we used the OpenSAFELY platform analyse routinely collected electronic primary care data linked national registrations. included all adults (aged ≥18 years) alive and follow-up Feb 1, 2020, at least 1 year continuous registration general...
<h2>Summary</h2><h3>Background</h3> COVID-19 has disproportionately affected minority ethnic populations in the UK. Our aim was to quantify differences SARS-CoV-2 infection and outcomes during first second waves of pandemic England. <h3>Methods</h3> We conducted an observational cohort study adults (aged ≥18 years) registered with primary care practices England for whom electronic health records were available through OpenSAFELY platform, who had at least 1 year continuous registration start...
Abstract The frequency of, and risk factors for, long COVID are unclear among community-based individuals with a history of COVID-19. To elucidate the burden possible causes in community, we coordinated analyses survey data from 6907 self-reported COVID-19 10 UK longitudinal study (LS) samples 1.1 million diagnostic codes electronic healthcare records (EHR) collected by spring 2021. Proportions presumed cases LS reporting any symptoms for 12+ weeks ranged 7.8% 17% (with 1.2 to 4.8%...
The SARS-CoV-2 B.1.1.7 variant of concern (VOC) is increasing in prevalence across Europe. Accurate estimation disease severity associated with this VOC critical for pandemic planning. We found increased risk death compared non-VOC cases England (hazard ratio: 1.67; 95% confidence interval: 1.34–2.09; p < 0.0001). Absolute by 28 days age and comorbidities. This has potential to spread faster higher mortality than the date.
Background Long COVID describes new or persistent symptoms at least 4 weeks after onset of acute COVID-19. Clinical codes to describe this phenomenon were recently created. Aim To the use long-COVID codes, and variation by general practice, demographic variables, over time. Design setting Population-based cohort study in English primary care. Method Working on behalf NHS England, OpenSAFELY data used encompassing 96% population between 1 February 2020 25 May 2021. The proportion people with...
The risk of severe COVID-19 outcomes in people with immune-mediated inflammatory diseases and on immune-modifying drugs might not be fully mediated by comorbidities vary factors such as ethnicity. We aimed to assess the adults those therapies.
Abstract Objective To compare the effectiveness of sotrovimab (a neutralising monoclonal antibody) with molnupiravir (an antiviral) in preventing severe outcomes covid-19 adult patients infected SARS-CoV-2 community and at high risk from covid-19. Design Observational cohort study OpenSAFELY platform. Setting With approval NHS England, a real world was conducted OpenSAFELY-TPP platform secure, transparent, open source software for analysis electronic health records), patient level record...
Abstract Objective To assess the association between learning disability and risk of hospital admission death from covid-19 in England among adults children. Design Population based cohort study on behalf NHS using OpenSAFELY platform. Setting Patient level data were obtained for more than 17 million people registered with a general practice that uses TPP software. Electronic health records linked Office National Statistics Secondary Uses Service. Participants Adults (aged 16-105 years)...
Objectives To assess the association between routinely prescribed non-steroidal anti-inflammatory drugs (NSAIDs) and deaths from COVID-19 using OpenSAFELY, a secure analytical platform. Methods We conducted two cohort studies 1 March to 14 June 2020. Working on behalf of National Health Service England, we used routine clinical data in England linked death data. In study 1, identified people with an NSAID prescription last 3 years general population. 2, rheumatoid arthritis/osteoarthritis....
Abstract Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) alpha variant (B.1.1.7) is associated with higher transmissibility than wild-type virus, becoming the dominant in England by January 2021. We aimed to describe severity of terms pathway disease from testing positive hospital admission and death. Methods With approval NHS England, we linked individual-level data primary care SARS-CoV-2 community testing, admission, Office for National Statistics all-cause...
Abstract Background On December 8th 2020, NHS England administered the first COVID-19 vaccination as part of an ambitious programme during a global health emergency. Aims To describe trends and variation in vaccine coverage by key clinical demographic groups; to create framework for near-real-time monitoring subgroups. Methods Working on behalf we analysed 57.9 million patient records situ within infrastructure Electronic Health Record (EHR) software vendors EMIS TPP using OpenSAFELY. We...
Abstract Objective To investigate whether risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and outcomes disease 2019 (covid-19) differed between adults living without children during the first two waves UK pandemic. Design Population based cohort study, on behalf NHS England. Setting Primary care data pseudonymously linked hospital intensive admissions death records from England, wave 1 (1 February to 31 August 2020) September 18 December 2020)....
Residents in care homes have been severely impacted by COVID-19. We describe trends the mortality risk among residents of compared to private homes. On behalf NHS England we used OpenSAFELY-TPP calculate monthly age-standardised risks death due all causes and COVID-19 adults aged >=65 years between 1/2/2019 31/03/2021. Care home were identified using linkage Quality Commission data. included 4,340,648 people 65 or older on 1st February 2019, 2.2% whom classified as residing a nursing home....
On 8 December 2020 NHS England administered the first COVID-19 vaccination.To describe trends and variation in vaccine coverage different clinical demographic groups 100 days of rollout.With approval England, a cohort study was conducted 57.9 million patient records general practice situ within infrastructure electronic health record software vendors EMIS TPP using OpenSAFELY.Vaccine across various subgroups Joint Committee on Vaccination Immunisation (JCVI) priority cohorts is described.A...
<ns4:p><ns4:bold>Background:</ns4:bold> Since its inception in March 2020, data from the OpenSAFELY-TPP electronic health record platform has been used for more than 20 studies relating to global COVID-19 emergency. is derived practices England using SystmOne software, and majority of these studies. We set out investigate representativeness by comparing it national population estimates. </ns4:p><ns4:p> <ns4:bold>Methods: </ns4:bold>With approval NHS England, we describe age, sex, Index...
To estimate waning of covid-19 vaccine effectiveness over six months after second dose.
Background There is concern about medium to long-term adverse outcomes following acute Coronavirus Disease 2019 (COVID-19), but little relevant evidence exists. We aimed investigate whether risks of hospital admission and death, overall by specific cause, are raised discharge from a COVID-19 hospitalisation. Methods findings With the approval NHS-England, we conducted cohort study, using linked primary care data in OpenSAFELY compare between people discharged hospitalisation (February...
Abstract Objective To compare the effectiveness of BNT162b2 mRNA (Pfizer-BioNTech) and mRNA-1273 (Moderna) covid-19 vaccines during booster programme in England. Design Matched cohort study, emulating a comparative trial. Setting Linked primary care, hospital, surveillance records available within OpenSAFELY-TPP research platform, covering period when SARS-CoV-2 delta omicron variants were dominant. Participants 3 237 918 adults who received dose either vaccine between 29 October 2021 25...
To ascertain patient eligibility status and describe coverage of antiviral drugs neutralising monoclonal antibodies (nMAB) as treatment for covid-19 in community settings England.Retrospective, descriptive cohort study, approved by NHS England.Routine clinical data from 23.4 million people linked to on infection treatment, within the OpenSAFELY-TPP database.Outpatients with at high risk severe outcomes.Nirmatrelvir/ritonavir (paxlovid), sotrovimab, molnupiravir, casirivimab/imdevimab, or...